Background
Methods
Study population
Measurements
Outcomes
Statistics
Results
Baseline characteristics
Men
| ||||
SUA tertiles | I ≤ 317μmol/L | II 318-380 μmol/L | III 381-976 μmol/L | P value for linear trend |
N | 896 | 902 | 898 | |
Age, years | 60 ± 10 | 59 ± 10 | 59 ± 11 | <0.001 |
Serum uric acid (SUA), μmol/L | 276 ±33 | 348 ± 18 | 449 ± 70 | - |
BMI, kg/m2
| 24.7 ± 2.9 | 25.8 ± 3.0 | 27.3 ± 3.4 | <0.001 |
SBP, mm Hg | 144 ± 20 | 144 ± 20 | 146 ± 20 | <0.001 |
DBP, mm Hg | 84 ± 12 | 85 ± 12 | 86 ± 12 | <0.001 |
Hypertension, n (%) | 482 (54%) | 546 (61%) | 571 (64%) | <0.001 |
Total cholesterol, mmol/l | 6.35 ± 1.19 | 6.40 ± 1.20 | 6.73 ± 1.20 | <0.001 |
HDL cholesterol, mmol/l | 1.51 ± 0.40 | 1.40 ± 0.39 | 1.26 ± 0.38 | <0.001 |
GFR ckd-epi, ml/min/1.73m2
| 96.7 (90.9, 102.4) | 95.5 (88.0, 102.5) | 93.4 (84.0, 101.5) | <0.001 |
ACR mg/mmol | 0.55 (0.38, 0.96) | 0.51 (0.33, 1.01) | 0.54 (0.34, 1.13) | 0.021 |
Use of antihypertensive drugs, n (%) | 74 (8%) | 87 (10%) | 155 (17%) | <0.001 |
Use of diuretics , n (%) | 2 (0.2%) | 5 (0.6%) | 13 (1.4%) | <0.001 |
Current smoker, n (%) | 351 (39%) | 300 (33%) | 294 (33%) | <0.001 |
Physically active, n (%) | 301 (33%) | 268 (30%) | 244 (27%) | <0.001 |
Women
| ||||
SUA tertiles | I ≤ 244 μmol/L | II 245-297 μmol/L | III 298-681 μmol/L | P value for linear trend |
N | 1002 | 1001 | 1001 | |
Age, years | 58 ± 11 | 60 ± 10 | 62 ± 9 | <0.001 |
Serum uric acid (SUA), μmol/L | 206 ± 28 | 269 ± 15 | 354 ± 54 | - |
BMI, kg/m2
| 24.0 ± 3.5 | 25.6 ± 3.8 | 27.7 ± 4,6 | <0.001 |
SBP, mm Hg | 138 ± 23 | 143 ± 23 | 151 ± 25 | <0.001 |
DBP, mm Hg | 78 ± 13 | 81 ± 12 | 85 ± 14 | <0.001 |
Hypertension, n (%) | 446 (45%) | 534 (53%) | 679 (68%) | <0.001 |
Total cholesterol, mmol/l | 6.63 ± 1.39 | 6.82 ± 1.29 | 7.14 ± 1.32 | <0.001 |
HDL cholesterol, mmol/l | 1.76 ± 0.43 | 1.69 ± 0.43 | 1.54 ± 0.42 | <0.001 |
GFR ckd-epi, ml/min/1.73m2
| 96.9 (90.5,103.0) | 93.6 (86.0, 99.4) | 89.7 (79.4, 97.1) | <0.001 |
ACR, mg/mmol | 0.62 (0.41, 0.96) | 0.58 (0.41, 0.93) | 0.64 (0.42, 1.14) | <0.001 |
Use of diuretics, n (%) | 3 (0.3%) | 7 (0.7%) | 39 (3.9%) | <0.001 |
Use of antihypertensive drugs, n (%) | 65 (6.5%) | 107 (11%) | 148 (15%) | <0.001 |
Current smoker, n (%) | 339 (34%) | 315 (32%) | 278 (28%) | 0.001 |
Physically active, n (%) | 162 (16%) | 177 (18%) | 118 (12%) | <0.002 |
The association of serum uric acid with renal function and CV risk factors
Men n = 2696 | Women n = 3004 | Men and women n = 5700 | |||||||
---|---|---|---|---|---|---|---|---|---|
β (95% CI*) | Std. β-coeffcent.ϯ
| P-value | β (95% CI*) | Std. β-coeffcent.ϯ
| P-value | β (95% CI*) | Std. β-coeffcent.ϯ
| P-value | |
Model 1
| |||||||||
Intercept | 175 (143, 208) | - | <0.001 | 71 (52, 90) | - | <0.001 | 128 (108, 148) | - | <0.001 |
Age | -0.70 (-0.10, -0.39) | -0.09 | <0.001 | 0.55 (0.30, 0.80) | 0.08 | <0.001 | -0.39 (-0.61, -0.17) | -0.05 | 0.001 |
BMI | 8.29 (7.38, 9.21) | 0.33 | <0.001 | 5.31 (4.73, 5.88) | 0.32 | <0.001 | 6.79 (6.21, 7.37) | 0.30 | <0.001 |
SBP | 0.06 (-0.10, 0.21) | 0.01 | 0.49 | 0.24 (0.13, 0.35) | 0.08 | < 0.001 | 0.24 (0.13, 0.35) | 0.06 | <0.001 |
Adjusted R2
| 0.12 | 0.15 | 0.10 | ||||||
Model 2
| |||||||||
HDL-cholesterol | -44.42 (-52.09, -36.76) | -0.22 | <0.001 | -27.68 (-33.12,-22.23) | -0.17 | <0.001 | -61.58 (-66.42, -56.74) | -0.32 | <0.001 |
Cholesterol | 10.12 (7.70, 12.54) | 0.15 | <0.001 | 6.38 (4.50, 8.26) | 0.12 | <0.001 | 6.33 (4.67, 7.99) | 0.10 | <0.001 |
Adjusted R2
| 0.17 | 0.18 | 0.19 | ||||||
Model 3
| |||||||||
Antihypertensive | |||||||||
Drugs | 26.10 (16.76, 35.44) | 0.10 | <0.001 | 14.19 (6.55, 21.83) | 0.06 | 0.001 | 20.37 (13.66, 27.08) | 0.07 | <0.001 |
Diuretics | 66.90 (33.13, 99.98) | 0.07 | <0.001 | 69.14 (51.01, 87.28) | 0.13 | <0.001 | 54.52 (35.75, 73.29) | 0.07 | <0.001 |
Adjusted R2
| 0.18 | 0.20 | 0.20 | ||||||
Model 4
| |||||||||
Current smoker | -7.73 (-13.81, -1.63) | -0.04 | 0.01 | 2.07 (-3.02, 7.16) | 0.01 | 0.4 | -0.80 (-5.23, 3.62) | -0.004 | 0.7 |
Physical activity | -7.29 (-13.56, -1.02) | -0.04 | 0.02 | 1.17 (-5.27, 7.61) | 0.01 | 0.7 | 11.28 (6.35, 16.20) | 0.05 | <0.001 |
Adjusted R2
| 0.19 | 0.20 | 0.20 | ||||||
Model 5
| |||||||||
GFR ckd-epi | -1.76 (-2.05, -1.48) | -0.28 | <0.001 | -1.73 (-1.94, -1.51) | -0.32 | <0.001 | -1.74 (-1.91,-1.56) | -0.27 | <0.001 |
logACR | 4.09 (-2.58, 10.76) | 0.02 | 0.23 | 15.41 (9.28, 21.55) | 0.08 | < 0.001 | 8.09 (3.58, 12.61) | 0.04 | <0.001 |
Gender | - - | - | - | - - | - | - | 76.87 (73.08, 80.66) | 0.44 | <0.001 |
Adjusted R2 | 0.23 | 0.27 | 0.40 |
Event rates
Associations between serum uric acid and outcome variables (Cox proportional hazard models)
Hazard ratio (95% CI) per 1 SD increase in serum uric acid (87 μmol/L) | ||||||
---|---|---|---|---|---|---|
Men (n = 2696) | P-value | Women (n = 3004) | P-value | Men and women ( n = 5700) | P-value | |
All-cause mortality
| ||||||
Unadjusted | 1.01 (0.94, 1.09) | 0.6 | 1.24 (1.14, 1.35) | <0.001 | 1.10 (1.04, 1.17) | <0.001 |
Age-adjusted | 1.11 (1.03, 1.19) | 0.005 | 1.12 (1.03, 1.22) | 0.008 | 1.11 (1,05, 1.18) | <0.001 |
Multivariable adjustment | ||||||
Model 1 | 1.13 (1.04, 1.22) | 0.003 | 1.22 (1.12, 1.33) | <0.001 | 1.19 (1.14, 1.25) | <0.001 |
Model 2 | 1.13 (1.05, 1.23) | 0.003 | 1.20 (1.10, 1.31) | 0.001 | 1.17 (1.01, 1.24) | <0.001 |
Model 3 | 1.13 (1.04, 1.22) | 0.005 | 1.20 (1.09, 1.32) | <0.001 | 1.16 (1,09, 1.23) | <0.001 |
Model 4 | 1.12 (1.04, 1.22) | 0.005 | 1.20 (1.09, 1.31) | <0.001 | 1.16 (1.09, 1.23) | <0.001 |
Model 5 | 1.11 (1.02, 1.20) | 0.02 | 1.16 (1.05, 1.29) | 0.004 | 1.13 (1.06, 1.21) | <0.001 |
Myocardial infarction
| ||||||
Unadjusted | 1.15 (1.05, 1.26) | 0.003 | 1.38 (1.20, 1.59) | <0.001 | 1.21 (1.12, 1.31) | <0.001 |
Age-adjusted | 1.22 (1.11, 1.34) | <0.001 | 1.21 (1.06, 1.40) | 0.006 | 1.23 (1.14, 1.33) | <0.001 |
Multivariable adjustment | ||||||
Model 1 | 1.16 (1.05, 1.28) | 0.004 | 1.16 (1.01, 1.35) | 0.049 | 1.16 (1.08, 1.27) | <0.001 |
Model 2 | 1.07 (0.95, 1.19) | 0.25 | 1.09 (0.93, 1.27) | 0.26 | 1.09 (0.99, 1.18) | 0.09 |
Model 3 | 1.05 (0.94, 1.17) | 0.3 | 1.10 (0.94, 1.29) | 0.22 | 1.09 (0.10, 1.18) | 0.06 |
Model 4 | 1.05 (0.95, 1.17) | 0.3 | 1.09 (0.93, 1.27) | 0.3 | 1.08 (0.99, 1.18) | 0.09 |
Model 5 | 1.05 (0.94, 1.17) | 0.4 | 1.06 (0.90, 1.25) | 0.5 | 1.06 (0.97, 1.16) | 0.19 |
Ischemic stroke
| ||||||
Unadjusted | 1.13 (1.01, 1.28) | 0.049 | 1.37 (1.17, 1.61) | <0.001 | 1.21 (1.10, 1.33) | <0.001 |
Age-adjusted | 1.23 (1.08, 1.40) | 0.001 | 1.20 (1.03, 1.40) | 0.02 | 1.22 (1.11, 1.35) | <0.001 |
Multivariable adjustment | ||||||
Model 1 | 1.25 (1.10, 1.42) | 0.001 | 1.13 (0.95, 1.33) | 0.17 | 1.19 (1.07, 1.31) | 0.001 |
Model 2 | 1.29 (1.13, 1.47) | <0.001 | 1.13 (0.95, 1.34) | 0.17 | 1.22 (1.09, 1.35) | <0.001 |
Model 3 | 1.28 (1.11, 1.46) | <0.001 | 1.13 (0.95, 1.35) | 0.18 | 1.21 (1.09, 1.35) | <0.001 |
Model 4 | 1.28 (1.12, 1.47) | <0.001 | 1.12 (0.94, 1.34) | 0.20 | 1.22 (1.09, 1.35) | <0.001 |
Model 5 | 1.31 (1.14, 1.50) | <0.001 | 1.13 (0.94, 1.36) | 0.21 | 1.24 (1.11, 1.38) | <0.001 |